Emergent Biosolutions spent $575K lobbying in 3Q

Published



Biopharmaceutical company Emergent BioSolutions Inc. spent $575,000 lobbying the federal government in the third quarter, according to a recent disclosure form.

The Rockville-based company lobbied on various agency appropriations and the government stockpiling of biodefense vaccines.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.